Attached files

file filename
10-K - ANNUAL REPORT - PLURISTEM THERAPEUTICS INCf10k2020_pluristemtherap.htm
EX-32.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2020ex32-2_pluristem.htm
EX-32.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2020ex32-1_pluristem.htm
EX-31.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2020ex31-2_pluristem.htm
EX-31.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2020ex31-1_pluristem.htm
EX-23.1 - CONSENT OF KOST FORER GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL - PLURISTEM THERAPEUTICS INCf10k2020ex23-1_pluristem.htm
EX-21.1 - LIST OF SUBSIDIARIES OF THE COMPANY - PLURISTEM THERAPEUTICS INCf10k2020ex21-1_pluristem.htm
EX-10.20 - FINANCE CONTRACT BETWEEN THE EUROPEAN INVESTMENT BANK, AS LENDER, AND PLURISTEM - PLURISTEM THERAPEUTICS INCf10k2020ex10-20_pluristem.htm
EX-10.19 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN PLURISTEM LTD. AND CHEN FRANCO - PLURISTEM THERAPEUTICS INCf10k2020ex10-19_pluristem.htm
EX-10.18 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN PLURISTEM LTD. AND YAKY YANAY - PLURISTEM THERAPEUTICS INCf10k2020ex10-18_pluristem.htm
EX-10.17 - AMENDED AND RESTATED CONSULTING AGREEMENT BETWEEN PLURISTEM LTD. AND ROSE HIGH T - PLURISTEM THERAPEUTICS INCf10k2020ex10-17_pluristem.htm
EX-4.3 - DESCRIPTION OF SECURITIES - PLURISTEM THERAPEUTICS INCf10k2020ex4-3_pluristem.htm
EX-3.4 - AMENDED AND RESTATED BY-LAWS AS AMENDED ON SEPTEMBER 10, 2020 (MARKED) - PLURISTEM THERAPEUTICS INCf10k2020ex3-4_pluristem.htm
EX-3.3 - AMENDED AND RESTATED BY-LAWS AS AMENDED ON SEPTEMBER 10, 2020 - PLURISTEM THERAPEUTICS INCf10k2020ex3-3_pluristem.htm

Exhibit 10.8

 

Summary of Directors Ongoing Compensation

 

Effective as September 10, 2020, our non-executive officer directors receive cash compensation as follows:

 

Annual compensation of $35,000;

 

The Chairman of our Audit Committee shall receive an additional annual fee of $10,000 and in the event of an annual equity grant issued to directors, or an Annual Director Grant, an additional 10% of equity securities in addition to such grant, and each other member of the Audit Committee shall receive an additional annual fee of $3,000 and, in the event of an Annual Director Grant, an additional 3% of equity securities in addition to such grant;

 

The Chairman of our Compensation Committee shall receive an additional annual fee of $4,000 and, in the event of an Annual Director Grant, an additional 4% of equity securities in addition to such grant, and each other member of the Compensation Committee shall receive an additional annual fee of $2,000 and, in the event of an Annual Director Grant, an additional 2% of equity securities in addition to such grant; and

 

The Chairman of our Nominating Committee shall receive an additional annual fee of $4,000 and, in the event of an Annual Director Grant, an additional 4% of equity securities in addition to such grant, and each other member of the Nominating Committee shall receive an additional annual fee of $2,000 and, in the event of an Annual Director Grant, an additional 2% of equity securities in addition to such grant.

 

In exceptional circumstances, our non-executive directors may receive bonuses of up to $75,000 per year for extraordinary performance, as well as discretionary bonuses in special circumstances as the Board of Directors or the Compensation Committee may decide.